SNRIs and Hyponatremia Risk

Introduction to SNRI-Induced Hyponatremia

The European Society of Cardiology recognizes SIADH as a significant adverse effect associated with SNRIs in their 2022 cardiovascular pharmacotherapy guidelines, highlighting the importance of monitoring sodium levels in patients on SNRIs, particularly in elderly populations 1

Age ≥65 years is the single strongest predictor of SNRI-induced hyponatremia, with elderly patients having decreased baroreceptor sensitivity, reduced total body water, and age-related decreases in glomerular filtration rate, making them more susceptible to hyponatremia 2
The American Geriatrics Society 2019 Beers Criteria added SNRIs to the list of antidepressant drug classes to avoid in persons with a history of falls or fractures, recognizing their contribution to hyponatremia-related complications, especially in elderly patients 3

Concomitant diuretic use, especially thiazides, dramatically amplifies hyponatremia risk and represents a potentially dangerous combination, as the combination of SNRIs with other SIADH-inducing medications substantially increases risk 4

The American Geriatrics Society recommends checking baseline serum sodium before initiating SNRI therapy in all patients ≥65 years, those on diuretics, or with other risk factors, and rechecking sodium within 2-4 weeks of initiation 5
For symptomatic hyponatremia, discontinue the SNRI immediately, and for severe symptomatic hyponatremia, administer 3% hypertonic saline, with monitoring of serum sodium every 2 hours initially 4

The American Geriatrics Society suggests considering nonserotonergic antidepressants, such as mirtazapine, which may be safer regarding hyponatremia risk, as an alternative to SNRIs in patients at high risk or with prior hyponatremia 6
Bupropion has been successfully used as replacement therapy in elderly patients who developed SSRI/SNRI-induced hyponatremia, leading to full recovery, although more research is needed to confirm its efficacy and safety 7